Literature DB >> 30887169

Cisplatin-based chemoradiotherapy vs. cetuximab-based bioradiotherapy for p16-positive oropharyngeal cancer: an updated meta-analysis including trials RTOG 1016 and De-ESCALaTE.

Petar Suton1, Marko Skelin2, Zoran Rakusic3, Stjepan Dokuzovic4, Ivica Luksic5.   

Abstract

PURPOSE: Human papilloma virus (HPV)-associated oropharyngeal cancer (OPC) is a special entity among head and neck squamous cell carcinomas (HNSCCs). Given its favorable prognosis, one of the de-escalating strategies in the treatment of OPC includes the introduction of cetuximab (C225) instead of cisplatin (CDDP) in conjunction with radiotherapy. An updated meta-analysis of published studies has been performed, which directly compared the efficacy of CDDP vs. C225 given concurrently with radiotherapy as definitive treatment of p16-positive OPC.
METHODS: A systematic literature search was performed for studies published between 2006 and 2018. A total of 1490 citations were obtained and 8 studies met inclusion criteria, with a total of 1665 patients.
RESULTS: The data from seven studies were available for the analysis of 2-year overall survival (OS). Calculated pooled OR for CDDP-based chemoradiotherapy vs. C225-based bioradiotherapy, was 0.45 (P < 0.0001). The data from eight studies were available for the analysis of 2-year locoregional recurrence (LRR). Calculated pooled OR for CDDP-based chemoradiotherapy vs. C225-based bioradiotherapy was 0.35 (P < 0.0001). Patients receiving CDDP with irradiation had 2.2- and 2.9-fold decreased risk for death from any cause and LRR, respectively.
CONCLUSIONS: For patients with HPV-positive OPC, radiotherapy plus C225 showed inferior OS and higher LRR rates compared with radiotherapy plus CDDP. CDDP-based chemoradiotherapy should remain standard of definitive treatment of p16-positive OPC.

Entities:  

Keywords:  Cetuximab; Cisplatin; Human papilloma virus; Oropharyngeal cancer; Recurrence; Survival

Mesh:

Substances:

Year:  2019        PMID: 30887169     DOI: 10.1007/s00405-019-05387-8

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  26 in total

1.  Human papillomavirus and survival of patients with oropharyngeal cancer.

Authors:  K Kian Ang; Jonathan Harris; Richard Wheeler; Randal Weber; David I Rosenthal; Phuc Felix Nguyen-Tân; William H Westra; Christine H Chung; Richard C Jordan; Charles Lu; Harold Kim; Rita Axelrod; C Craig Silverman; Kevin P Redmond; Maura L Gillison
Journal:  N Engl J Med       Date:  2010-06-07       Impact factor: 91.245

2.  Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients.

Authors:  Jean-Pierre Pignon; Aurélie le Maître; Emilie Maillard; Jean Bourhis
Journal:  Radiother Oncol       Date:  2009-05-14       Impact factor: 6.280

3.  Concomitant radiochemotherapy vs radiotherapy alone in patients with head and neck cancer: a Hellenic Cooperative Oncology Group Phase III Study.

Authors:  George Fountzilas; Elisabeta Ciuleanu; Urania Dafni; George Plataniotis; Anna Kalogera-Fountzila; Epaminontas Samantas; Eleni Athanassiou; John Tzitzikas; Tudor Ciuleanu; Angelos Nikolaou; Panayiotis Pantelakos; Thomas Zaraboukas; Nikolaos Zamboglou; John Daniilidis; Nicolas Ghilezan
Journal:  Med Oncol       Date:  2004       Impact factor: 3.064

4.  Locoregionally advanced head and neck cancer treated with primary radiotherapy: a comparison of the addition of cetuximab or chemotherapy and the impact of protocol treatment.

Authors:  Jimmy J Caudell; Stephen M Sawrie; Sharon A Spencer; Renee A Desmond; William R Carroll; Glenn E Peters; Lisle M Nabell; Ruby F Meredith; James A Bonner
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-03-20       Impact factor: 7.038

5.  Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial.

Authors:  Carole Fakhry; William H Westra; Sigui Li; Anthony Cmelak; John A Ridge; Harlan Pinto; Arlene Forastiere; Maura L Gillison
Journal:  J Natl Cancer Inst       Date:  2008-02-12       Impact factor: 13.506

6.  Human papillomavirus is a favourable prognostic factor in tonsillar cancer and its oncogenic role is supported by the expression of E6 and E7.

Authors:  David Lindquist; Mircea Romanitan; Lalle Hammarstedt; Anders Näsman; Hanna Dahlstrand; Johan Lindholm; Liselotte Onelöv; Torbjörn Ramqvist; Weimin Ye; Eva Munck-Wikland; Tina Dalianis
Journal:  Mol Oncol       Date:  2007-09-01       Impact factor: 6.603

7.  Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.

Authors:  James A Bonner; Paul M Harari; Jordi Giralt; Roger B Cohen; Christopher U Jones; Ranjan K Sur; David Raben; Jose Baselga; Sharon A Spencer; Junming Zhu; Hagop Youssoufian; Eric K Rowinsky; K Kian Ang
Journal:  Lancet Oncol       Date:  2009-11-10       Impact factor: 41.316

8.  Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.

Authors:  James A Bonner; Paul M Harari; Jordi Giralt; Nozar Azarnia; Dong M Shin; Roger B Cohen; Christopher U Jones; Ranjan Sur; David Raben; Jacek Jassem; Roger Ove; Merrill S Kies; Jose Baselga; Hagop Youssoufian; Nadia Amellal; Eric K Rowinsky; K Kian Ang
Journal:  N Engl J Med       Date:  2006-02-09       Impact factor: 91.245

9.  Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis.

Authors:  Mitchell Machtay; Jennifer Moughan; Andrew Trotti; Adam S Garden; Randal S Weber; Jay S Cooper; Arlene Forastiere; K Kian Ang
Journal:  J Clin Oncol       Date:  2008-06-16       Impact factor: 44.544

10.  Surgery and adjuvant radiotherapy vs concurrent chemoradiotherapy in stage III/IV nonmetastatic squamous cell head and neck cancer: a randomised comparison.

Authors:  K-C Soo; E-H Tan; J Wee; D Lim; B-C Tai; M-L Khoo; C Goh; S-S Leong; T Tan; K-W Fong; P Lu; A See; D Machin
Journal:  Br J Cancer       Date:  2005-08-08       Impact factor: 7.640

View more
  7 in total

1.  Cisplatin-based chemoradiotherapy trumps cetuximab-based bioradiotherapy in p16/HPV-positive oropharyngeal cancers.

Authors:  Monali Swain; Tejpal Gupta; Sadhana Kannan; JaiPrakash Agarwal
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-04-25       Impact factor: 2.503

2.  In reply to Swain et al.: Re-evaluation of updated meta-analysis including trials RTOG 1016 and De-ESCALaTE.

Authors:  Petar Suton; Marko Skelin; Zoran Rakusic; Stjepan Dokuzovic; Ivica Luksic
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-05-27       Impact factor: 2.503

3.  De-Escalated Adjuvant Therapy After Transoral Robotic Surgery for Human Papillomavirus-Related Oropharyngeal Carcinoma: The Sinai Robotic Surgery (SIRS) Trial.

Authors:  Brett A Miles; Marshall R Posner; Vishal Gupta; Marita S Teng; Richard L Bakst; Mike Yao; Kryzsztof J Misiukiewicz; Raymond L Chai; Sonam Sharma; William H Westra; Seunghee Kim-Schulze; Bheesham Dayal; Stanislaw Sobotka; Andrew G Sikora; Peter M Som; Eric M Genden
Journal:  Oncologist       Date:  2021-03-18

4.  A Critical Role for p53 during the HPV16 Life Cycle.

Authors:  Christian T Fontan; Claire D James; Apurva T Prabhakar; Molly L Bristol; Raymonde Otoa; Xu Wang; Elmira Karimi; Pavithra Rajagopalan; Devraj Basu; Iain M Morgan
Journal:  Microbiol Spectr       Date:  2022-05-24

Review 5.  Comparative efficacy and safety of radiotherapy/cetuximab versus radiotherapy/chemotherapy for locally advanced head and neck squamous cell carcinoma patients: a systematic review of published, primarily non-randomized, data.

Authors:  Mei Mei; Yu-Huan Chen; Tian Meng; Ling-Han Qu; Zhi-Yong Zhang; Xiao Zhang
Journal:  Ther Adv Med Oncol       Date:  2020-12-08       Impact factor: 8.168

Review 6.  Molecular mechanisms underlying increased radiosensitivity in human papillomavirus-associated oropharyngeal squamous cell carcinoma.

Authors:  Huanhuan Wang; Bin Wang; Jinlong Wei; Lingbin Meng; Qihe Zhang; Chao Qu; Ying Xin; Xin Jiang
Journal:  Int J Biol Sci       Date:  2020-02-04       Impact factor: 6.580

7.  LMNA functions as an oncogene in hepatocellular carcinoma by regulating the proliferation and migration ability.

Authors:  Heng Liu; Dongming Li; Ling Zhou; Shuang Kan; Guozhang He; Kun Zhou; Liping Wang; Ming Chen; Wei Shu
Journal:  J Cell Mol Med       Date:  2020-09-08       Impact factor: 5.310

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.